Clinical trials: Keratitis
Neurotrophic Keratitis
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people…
- Trial name
- EMERALD-1 (NCT06999733)
- Testing
- KB801
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Krystal Biotech, Inc.
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Keratoconjunctivitis Sicca
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
- Trial name
- NCT00851734
- Testing
- voclosporin ophthalmic solution
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lux Biosciences, Inc.
Keratoconjunctivitis, Conjunctivitis
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567918
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Corneal Ulcer
Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing
CACICOL20 is a biodegradable nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Applied to the corneal lesion, it replaces damaged heparan sulfates in the matrix scaffold.
- Trial name
- UNICOL (NCT01242839)
- Testing
- CACICOL20
- Where
- 21 sites in France
- Volunteers
- 139 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Keratoconjunctivitis, Ocular Surface Disease
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
- Trial name
- NCT03769454
- Testing
- PP-001
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Panoptes Pharma GmbH
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Neurotrophic Keratitis
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Primary Objective To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
- Trial name
- NCT05552261
- Testing
- Cenegemin in the DEFENDO Study
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dompé Farmaceutici S.p.A
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Dry Eye Syndromes
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
This study is a prospective, multicentre, parallel-group, active-controlled, non-inferiority study conducted in adult patients with moderate-to-severe dry eye disease (DED) related to keratitis or keratoconjunctivitis.
- Trial name
- PROSIKA (NCT04701086)
- Testing
- Cationorm Pro, Vismed
- Where
- 8 sites in France, Poland and 1 more
- Volunteers
- 83 people
- Sponsor
- Santen SAS
Corneal Ulcer
Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer
This study is to develop a lamellar keratoplasty method for corneal ulcer using acellular corneal matrix (ACM) and to make an analysis among patients for its therapeutic effect.
- Trial name
- NCT01244776
- Testing
- acellular corneal matrix
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shaanxi Aierfu Activtissue Engineering
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Keratitis
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
We will need about 36 participants for this study. Volunteers might be able to participate if: they have bad noninfectious keratitis early treatments failed or were not well tolerated Participants will be in the study for about…
- Trial name
- NCT04169061
- Testing
- Acthar
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mallinckrodt
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
- Trial name
- NCT06370039
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Invirsa, Inc.
Herpes Simplex Virus Type I Stromal Keratitis
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation…
- Trial name
- NCT06474442
- Testing
- BD111 Injection (investigational new drug), Triple-drugs therapy of HSV-1 stromal keratitis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Infectious Keratitis
Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis
This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.
- Trial name
- NCT01739673
- Testing
- Ultraviolet-A and riboflavin
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cxlusa
Acanthamoeba Keratitis
Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/ml Polihexanide
This will be a non-interventional study with secondary use of data. The study will be a site-based retrospective review of medical chart of patients with AK who initiated and completed a treatment with 0.8 mg/ml polihexanide as…
- Trial name
- NCT06641882
- Where
- 10 sites in Italy
- Volunteers
- 40 people
- Sponsor
- SIFI SpA
Keratitis
Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered…
- Trial name
- FAST (NCT03237936)
- Testing
- 1mg/mL ciclosporin
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Santen SAS
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA